Poster number |
Title |
Submitting author |
City and Country |
265 |
Cardiovascular Events Among Adult Patients with Aggressive B-Cell Lymphoma Treated with Standard of Care Axicabtagene Ciloleucel and Tisagenlecleucel |
Raphael Steiner |
Houston, TX, USA |
266 |
Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel (Tisa-cel) Infusion in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/r FL) |
Nathan Fowler |
Houston, TX, USA |
267 |
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma: Updated analysis of the phase 1b PORTIA study |
Ulrich Jaeger |
Vienna, Austria |
268 |
Relapse characterization in diffuse large B cell lymphoma patients undergoing commercial CAR-T cell therapy: experience from a single centre |
Mariana Bastos-Oreiro |
Madrid, Spain |
269 |
A single-arm, open-label, pilot trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-lymphoblastic leukemia/lymphoma |
Mingzhi Zhang |
Zhengzhou, China |
270 |
Patients with out of specification Tisagenlecleucel can be salvaged with a point-of-care CAR T-cells: An observational intention-to-treat single-center analysis |
Shalev Fried |
Tel Hashomer, Israel |
271 |
Extranodal Disease Is Associated with Shorter Progression-free Survival after CD19-CAR T-cell Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Veit Bücklein |
Munich, Germany |
272 |
Comparative efficacy of Tisagenlecleucel (tisa-cel) and Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) |
Richard Maziarz |
Portland, OR, USA |
273 |
OUTREACH: Preliminary Safety & Efficacy Results From a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting |
John Godwin |
Portland, OR, USA |
274 |
Outcome determinants of commercial CAR-T cell therapy for large B-cell lymphoma: results of the GLA/DRST Real World Analysis |
Peter Dreger |
Muenster, Germany |
275 |
FIRST REPORT OF THE REAL-LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR-T CELL IN DIFFUSE LARGE B-CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY |
Annalisa Chiappella |
Milano, Italy |
276 |
FDG-PET imaging and radiomics in response assessment of lymphoma patients undergoing CAR T-cell therapy |
Beatrice Casadei |
Bologna, Italy |
277 |
QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS TREATED WITH ANTI-CD19 CAR T-CELLS |
Anna Dodero |
Milano, Italy |
278 |
Resistance of B-cell lymphomas to CAR-T cell therapy is associated with histophenotypical and genomic tumor changes which can induce profound trans-differentiation |
Camille Laurent |
Toulouse, France |
279 |
In vitro analysis predicts clinical response of B cell lymphatic malignancies to CD19 CAR-T cells: phenotypic, transcriptional and functional study |
Katia Beider |
Ramat Gan, Israel |